Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

New FDA approvals in July include therapies for NSCLC, relapsed multiple myeloma, liver cancer, and B-cell malignancies.

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA ...

Only USDA approval of the Wilson, North Carolina, facility is needed before the Israeli company can start selling cultivated ...

The Food and Drug Administration has approved a vagus nerve bioimplant to treat rheumatoid arthritis (RA). The scientific ...

The FDA has approved Anzupgo (delgocitinib) cream for the topical treatment of moderate to severe chronic hand eczema in ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

A first-of-its-kind implant has just been granted approval from the US Food and Drug Administration (FDA) for the treatment ...

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally ...